Highlight

1.Novel anti-tumor strategy

1) B7-H3 are highly expressed in many different types of solid tumor, but has low expression levels in normal tissue. B7-H3 plays an important role in inhibiting T-cell function and promoting cancer progression and invasion. B7-H3 high expression remains poor prognosis and patient survival.

2) B7-H3×CD3 bispecific antibody can mediate cytotoxic activities against B7-H3-positive tumor cells by improving T cell activation.

2.Asset binds to CD3 and B7-H3 antigen simultaneously.

3.Excellent anti-tumor efficacy in vitro and in vivo.

1) Asset redirected T-Cell activation to kill B7-H3⁺ AsPC-1 (pancreatic cancer) and NCI-N87 (gastric cancer).

2) Asset suppresses tumor growth in NCI-N87 xenograft model

4.Good safety in preclinical study.

1) Asset shows positive safety profile in toxicity studies with Cynomolgus Monkeys.

✓There were no animal death and no adverse effects

✓No liver impairment was observed, compared to other BsAb target CD3 and B7-H3.

✓ Asset induced very low cytokine release(IL-2, IL-6, TNF-α, IFN-γ) in Cynomolgus monkeys.

2) Asset is well-tolerated in Cyno monkeys and the NOAEL is the highest dose tested at 3.6 mg/kg once weekly for 4 consecutive weeks (5 doses in total).

5.Innovative BsAb development platform

1) After reasonable design of heavy and light chains, , the mismatch probability of asset is greatly reduced.

2) Creative CMC, which greatly simplified production and purification process, through one step affinity chromatography the purity can be higher than 95%.

3) The platform brings a much lower cost of production.

Research progress：

IND stage;
Good anti-tumor efficacy in animal model;
Good safety;
Innovative CMC that lowers the cost of production